Esperion Therapeutics, Inc. — Director's Dealing 2022

May 18, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Esperion Therapeutics, Inc. (ESPR)
CIK: 0001434868
Period of Report: 2022-05-17

Reporting Person: Warren Eric (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-05-17	Common Stock	S	196	$5.981	Disposed	53910	Direct

Footnotes

F1: Shares were sold to satisfy tax obligation on quarterly vested shares of restricted stock units.